Success Metrics

Clinical Success Rate
100.0%

Based on 6 completed trials

Completion Rate
100%(6/6)
Active Trials
2(22%)
Results Posted
33%(2 trials)

Phase Distribution

Ph phase_3
3
33%
Ph phase_2
2
22%
Ph phase_1
1
11%
Ph phase_4
2
22%

Phase Distribution

1

Early Stage

2

Mid Stage

5

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
1(12.5%)
Phase 2Efficacy & side effects
2(25.0%)
Phase 3Large-scale testing
3(37.5%)
Phase 4Post-market surveillance
2(25.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

6 of 6 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

9

all time

Status Distribution
Active(2)
Completed(6)
Other(1)

Detailed Status

Completed6
Recruiting2
unknown1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
2
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (12.5%)
Phase 22 (25.0%)
Phase 33 (37.5%)
Phase 42 (25.0%)

Trials by Status

unknown111%
recruiting222%
completed667%

Recent Activity

2 active trials
Showing 5 of 9
recruitingphase_2

ATORvastatin in Pulmonary TUBerculosis: a POPulation PharmacoKinetics -PharmacoDynamics Sub-study (ATORTUB popPK-PD)

NCT07303699
completed

Effect of Genetic Variation on Efficacy and Safety of Lipid-Lowering Drugs

NCT07008794
recruitingphase_4

Impact of Atorvastatin Versus Rosuvastatin on 25 Hydroxy Vitamin D Levels in Patients With Acute Coronary Syndrome

NCT06765265
completedphase_3

A Study to Assess the Cholesterol Lowering Effect of Ezetimibe/Simvastatin Combination Tablet Compared to Another Cholesterol Lowering Drug in Elderly Patients With High Cholesterol at High or Moderately High Risk for Coronary Heart Disease (0653A-128)

NCT00535405
completedphase_3

Ezetimibe/Simvastatin (10 mg/40 mg) vs. the Doubling of Atorvastatin in High Risk Participants (MK-0653A-134 AM1)(COMPLETED)

NCT00782184
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT07303699Phase 2

ATORvastatin in Pulmonary TUBerculosis: a POPulation PharmacoKinetics -PharmacoDynamics Sub-study (ATORTUB popPK-PD)

Recruiting
NCT07008794

Effect of Genetic Variation on Efficacy and Safety of Lipid-Lowering Drugs

Completed
NCT06765265Phase 4

Impact of Atorvastatin Versus Rosuvastatin on 25 Hydroxy Vitamin D Levels in Patients With Acute Coronary Syndrome

Recruiting
NCT00535405Phase 3

A Study to Assess the Cholesterol Lowering Effect of Ezetimibe/Simvastatin Combination Tablet Compared to Another Cholesterol Lowering Drug in Elderly Patients With High Cholesterol at High or Moderately High Risk for Coronary Heart Disease (0653A-128)

Completed
NCT00782184Phase 3

Ezetimibe/Simvastatin (10 mg/40 mg) vs. the Doubling of Atorvastatin in High Risk Participants (MK-0653A-134 AM1)(COMPLETED)

Completed
NCT03867110Phase 3

An Efficacy and Safety Study of Ezetimibe (MK-0653, SCH 58235) in Addition to Atorvastatin Compared to Placebo in Participants With Primary Hypercholesterolemia (MK-0653-013)

Completed
NCT06053983Phase 4

Comparison Between Atorvastatin and Rosuvastatin in Reduction of Inflammatory Biomarkers in Patients With Acute Coronary Syndrome

Completed
NCT04221321Phase 1

Effect of Tegoprazan or RAPA114 on Pharmacokinetic of Atorvastatin in Healthy Adult Volunteers

Completed
NCT02791958Phase 2

Pharmacodynamic Equivalence of Ramipril 10 mg and Atorvastatin 40 mg Administered as a Cardiovascular (CV) Polypill Acetylsalicylic Acid-Atorvastatin-Ramipril (AAR) as Compared to Monotherapy

Unknown

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9